ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1476

Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus

Rosa Arvizu-Rivera1, jiram torres-Ruiz2, Alfredo Pérez-Fragoso2, Beatriz Alcalá-Carmona3, Miroslava Nuñez-Aguirre4, Ana Sofía Vargas-Castro4, Abdiel Absalón-Aguilar3, Jaquelin Lira-Luna4 and Diana Gómez-Martín2, 1Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, 2INCMNSZ, Ciudad de México, Mexico, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 4Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), Nephritis, neutrophils, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Enhanced netosis has been acknowledged as pathogenic in Systemic Lupus Erythematosus (SLE). The presence of antibodies against neutrophil extracellular traps (anti-NETs) in patients with SLE might contribute to deficient degradation of NETs in these patients. Additionally, anti-NET antibodies can bind to NETs and form immune complexes and increase NET formation by neutrophils. Previously, the presence of antibodies against components of NETs has been associated with proteinuria, activity index in lupus nephritis and increased SLEDAI. However, there is scarce information about the prevalence of anti-NET antibodies and their correlation with clinical characteristics of SLE patients.

We aimed to analyze the prevalence of IgG anti-NET antibodies and their association with disease activity and clinical features in patients with SLE.

Methods: We included patients older than 18 years old who fulfilled the ACR/SLICC 2012 classification criteria for SLE. Exclusion criteria included pregnancy, overlap syndrome, malignancy, and recent COVID-19 infection. NETs were quantified ex vivo and IgG anti-NETs were detected using ELISA as previously described. Twenty-three healthy controls were included to establish the cut-off point for anti-NETs, resulting in a cut-off point of 0.076 AU (OD). Correlations between non parametric variables were performed using Spearman’s rho.

Results: A total of 87 patients with SLE were included. The majority were women (88%) with a median age of 31.13 years. Their main clinical features as depicted in Table 1. Median levels of anti-NET antibodies were 0.30 OD, and 31 patients (35.6%) were considered to have anti-NET antibodies positivity. Patients were divided according to their clinical manifestations and analyzed for anti-NET antibodies positivity; results are shown in Table 2. Besides, we analyzed correlations between anti-NET antibodies levels and levels of SLEDAI, C3, C4, absolute lymphocyte count and anti-dsDNA (Table 3). A statistically significant positive correlation between anti-NET antibodies with SLEDAI (r=0.245) and anti-dsDNA antibodies (r=0.290) was found.

Conclusion: IgG anti-NET antibodies were found in approximately one third of SLE patients, Higher prevalence of antibody positivity was found in SLE patients with serological activity, serositis and lupus nephritis. Increased levels of anti-NET antibodies correlated with increased SLEDAI and anti-dsDNA titers. To our knowledge, this is the first description of the association between IgG anti-NET and clinical features of SLE. Their characterization might allow us to address their role as potential novel biomarkers.

Supporting image 1

Table 1. Clinical and laboratory features of SLE patients

Supporting image 2

Table 2. Anti-NET antibodies positivity in SLE patients according to clinical manifestations

Supporting image 3

Table 3. Correlations between levels of IgG anti-NET antibodies and SLEDAI, C3, C4, lymphocyte count and anti-dsDNA.


Disclosures: R. Arvizu-Rivera, None; j. torres-Ruiz, None; A. Pérez-Fragoso, None; B. Alcalá-Carmona, None; M. Nuñez-Aguirre, None; A. Vargas-Castro, None; A. Absalón-Aguilar, None; J. Lira-Luna, None; D. Gómez-Martín, None.

To cite this abstract in AMA style:

Arvizu-Rivera R, torres-Ruiz j, Pérez-Fragoso A, Alcalá-Carmona B, Nuñez-Aguirre M, Vargas-Castro A, Absalón-Aguilar A, Lira-Luna J, Gómez-Martín D. Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/anti-neutrophil-extracellular-traps-net-antibodies-and-their-association-with-disease-activity-and-clinical-phenotypes-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-neutrophil-extracellular-traps-net-antibodies-and-their-association-with-disease-activity-and-clinical-phenotypes-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology